<DOC>
	<DOCNO>NCT00909948</DOCNO>
	<brief_summary>The propose study base observation paradoxical tumor regression rejection donor graft conjunction result murine experiment . We hypothesize clinically meaningful response achieve patient advanced malignancy transplant strategy use nonmyeloablative conditioning relate mismatch donor stem cell transplant intention initially achieve mixed chimerism follow recipient lymphocyte infusion ( RLI ) attempt deliberately reject donor graft . This lead development novel transplant strategy achieve antitumor effect without risk graft versus host disease ( GVHD ) . This propose protocol Pilot Study evaluate safety outpatient transplant strategy , i.e. , establishment initial mixed chimerism follow RLI donor graft rejection , patient advance lymphoma , multiple myeloma . In addition , RLI report reverse ongoing GVHD , approach might potentially reverse GVHD achieve antitumor response complication unexpectedly occur .</brief_summary>
	<brief_title>Intentional Rejection Donor Graft Using Recipient Leukocyte Infusion ( ) Following Nonmyeloablative Allogeneic Stem Cell Transplant</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>1 . Patients chemorefractory nonHodgkin 's Hodgkin 's lymphoma multiple myeloma . Criteria consideration enrollment include : 1. primary refractory refractory relapse disease autologous HCT unlikely beneficial ; 2. relapse autologous HCT 3. ineligibility standard myeloablative nonmyeloablative alloHCT either lack donor patient consideration 2 . Non Hodgkin 's lymphoma , Hodgkin 's lymphoma : primary refractory refractory relapse 3 . Multiple myeloma ; primary refractory refractory relapse 4 . Patients malignancies previous autologous allogeneic bone marrow stem cell transplant . 5 . An estimated diseasefree survival less one year . 6 . Age 18 age &lt; 75 year 7 . ECOG performance status 0 , 1 , 2 . 1 . Patients whose life expectancy limit disease malignancy 2 . Patients 5/6 well match related donor 4/6 well umbilical cord blood donor medically eligible conventional myeloablative nonmyeloablative transplant exclude 3 . Cardiac disease : symptomatic congestive heart failure RVG echocardiogram determine LVEF ogf &lt; 30 % , active angina pectoris uncontrolled hypertension 4 . Pulmonary disease : severe chronic obstructive lung disease , symptomatic restrictive lung disease , correct DLCO &lt; 40 % predict 5 . Renal disease : serum creatinine &gt; 3.0 mg/dl . 6 . Hepatic disease : serum bilirubin &gt; 3.0 mg/dl alkaline phosphatase , SGOT SGPT &gt; 3 x ULN 7 . Neurologic disease : symptomatic leukoencephalopathy , active CNS malignancy neuropsychiatric abnormality believe preclude transplantation ( pervious CNS malignancy presently CR exclusion ) 8 . Uncontrolled infection . 9 . Recipient leukocyte infusion ( RLI ) might involve infusion circulate tumor cell patient . To minimize risk patient evidence circulate tumor cell light microscopy flow cytometry exclude 10 . Patients acute leukemia exclude likely much great circulate tumor burden , would increase risk infusion clonal tumor cell</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Related stem cell transplant ,</keyword>
	<keyword>TBI ,</keyword>
	<keyword>Mismatched stem cell transplant</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Non-myeloablative</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Multiple myeloma</keyword>
</DOC>